Functional interaction between α2-adrenoceptors, μ- and κ-opioid receptors in the guinea pig myenteric plexus: Effect of chronic desipramine treatment

European Journal of Pharmacology

Volumn 553, Issue 1-3, 2006, Pages 269-279

  Canciani, Luca ^a   Giaroni, Cristina ^a   Zanetti, Elena ^a   Giuliani, Daniela ^a   Pisani, Rossana ^a   Moro, Elisabetta ^a   Trinchera, Marco ^a   Crema, Francesca ^a   Lecchini, Sergio ^a   Frigo, Gianmario ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

2 adrenoceptor; opioid receptor; opioid receptor; Chronic desipramine treatment; Myenteric plexus; Sympathetic innervation

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; BRIMONIDINE; DESIPRAMINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; G PROTEIN COUPLED RECEPTOR KINASE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR AGONIST; MESSENGER RNA; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; ANALGESIC AGENT; BENZENEACETAMIDE DERIVATIVE; G PROTEIN COUPLED INWARDLY RECTIFYING POTASSIUM CHANNEL; GUANINE NUCLEOTIDE BINDING PROTEIN; NARCOTIC ANALGESIC AGENT; PYRROLIDINE DERIVATIVE; QUINOXALINE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COLON; CONTROLLED STUDY; DRUG EFFECT; GUINEA PIG; HOMEOSTASIS; IMMUNOREACTIVITY; INTESTINE INNERVATION; MALE; MYENTERIC PLEXUS; NONHUMAN; PERISTALSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SYMPATHETIC INNERVATION; ANIMAL; BIOSYNTHESIS; DRUG POTENTIATION; IN VITRO STUDY; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYNAPTOSOME; WESTERN BLOTTING;

ADRENERGIC ALPHA-AGONISTS; ANALGESICS; ANALGESICS, OPIOID; ANIMALS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZENEACETAMIDES; BLOTTING, WESTERN; DESIPRAMINE; ENKEPHALIN, ALA(2)-MEPHE(4)-GLY(5)-; G PROTEIN-COUPLED INWARDLY-RECTIFYING POTASSIUM CHANNELS; GTP-BINDING PROTEINS; GUINEA PIGS; MALE; MYENTERIC PLEXUS; PERISTALSIS; PYRROLIDINES; QUINOXALINES; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SYNAPTOSOMES;

EID: 33751166376     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.09.025     Document Type: Article

References (75)

1. Aghajanian G.K., and Wang Y.Y. Common alpha 2- and opiate effector mechanisms in the locus coeruleus: intracellular studies in brain slices. Neuropharmacology 26 (1987) 793-799
2. 1 antinociception, tolerance and withdrawal. J. Neurosci. 17 (1997) 735-744
3. 2-adrenoceptors. J. Neurochem. 53 (1989) 1629-1635
4. Ammer H., and Schulz R. Retinoic acid-induced differentiation of human neuroblastoma SH-SY5Y cells is associated with changes in the abundance of G proteins. J. Neurochem. 62 (1994) 1310-1318
5. Ammer H., Nice L., Lang J., and Schulz R. Regulation of G-proteins by chronic opiate and clonidine treatment in the guinea pig myenteric plexus. J. Pharmacol. Exp. Ther. 258 (1991) 790-796
6. Ammon-Treiber S., and Hollt V. Morphine-induced changes of gene expression in the brain. Addict. Biol. 10 (2005) 81-89
7. Barturen F., and García-Sevilla J.A. Long term treatment with desipramine increases the turnover of alpha2-adrenoceptors in the rat brain. Mol. Pharmacol. 42 (1992) 846-855
8. Benkelfat C., Aulakh C.S., Bykov V., Rice K.C., De Costa B.R., and Rothman R.B. Apparent down-regulation of rat brain μ- and κ-opioid binding sites labeled with [3H]cycloFOXY following chronic administration of the potent 5-hydroxytryptamine reuptake blocker, clomipramine. J. Pharm. Pharmacol. 41 (1989) 865-867
9. Bevilacqua A., Ceriani M.C., Capaccioli S., and Nicolin A. Post-transcriptional regulation of gene expression by degradation of messenger RNAs. J. Cell. Physiol. 195 (2003) 356-372
10. 2-adrenoceptors in the presence of experimental colitis. Br. J. Pharmacol. 139 (2003) 309-320
11. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
12. Briley M. Clinical experience with dual action antidepressants in different chronic pain syndromes. Hum. Psycopharmacol. Clin. Exp. 19 (2004) S21-S25
13. Browning K.N., Cunningham S.M.C., Duncan L., Timmermans J.P., and Lees G.M. Regional differences in the sympathetic innervation of the guinea-pig large intestine by neuropeptide Y and tyrosine hydroxylase-immunoreactive nerves of divergent extrinsic origin. J. Comp. Neurol. 410 (1999) 515-530
14. 2a-adrenoceptor mRNA in brain. Mol. Brain Res. 45 (1997) 154-158
15. Chakrabarti S., Oppermann M., and Gintzler A.R. Chronic morphine induces the concomitant phosphorylation and altered association of multiple signalling proteins: a novel mechanism for modulating cell signalling. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 4209-4214
16. Chalberg S.C., Duda T., Rhine J.A., and Sharma R.K. Molecular cloning, sequencing and expression of an alpha2-adrenergic receptor complementary DNA from rat brain. Mol. Cell. Biochem. 97 (1990) 161-172
17. Chen F., and Lawrence A.J. Chronic antidepressant treatment causes a selective reduction of μ-opioid receptor binding and functional coupling to G proteins in the amygdala of Fawn-Hooded rats. J. Pharmacol. Exp. Ther. 310 (2004) 1020-1026
18. 2-adrenoceptors in human vascular smooth muscle cells. Am. J. Physiol, Heart Circ. Physiol. 286 (2004) H59-H67
19. Clinton S.M., Sucharski I.L., and Finlay J.M. Desipramine attenuates working memory impairments induced by partial loss of catecholamines in the rat medial prefrontal cortex. Psycopharmacology 183 (2006) 404-412
20. Connor M., and Christie M.J. Opioid receptor signalling mechanisms. Clin. Exp. Pharmacol. Physiol. 26 (1999) 493-499
21. 2-adrenoceptor blockade. Neurosci. Lett. 222 (1997) 75-78
22. Costa M., and Brookes S.J.H. The enteric nervous system. Am. J. Gastroenterol. 89 (1994) S129-S137
23. de Gandarias J.M., Casis O., Varona A., Gallego M., Irazusta J., and Casis L. Interaction mechanisms of imipramine and desipramine with enkephalin-degrading aminopeptidases in vitro. Life Sci. 61 21 (1997) L321-L326
24. de Gandarias J.M., Echevarría E., Acebes I., Silio M., and Casis L. Effects of imipramine administration on mu-opioid receptor immunostaining in the rat forebrain. ArzneimittelForschung 48 (1998) 717-719
25. De Luca A., and Coupar I.M. Insights into opioid action in the intestinal tract. Pharmacol. Ther. 69 (1996) 103-115
26. De Paermentier F., Mauger J.M., Lowther S., Crompton M.R., Katona C.L.E., and Horton R.W. Brain α-adrenoceptors in depressed suicides. Brain Res. 757 (1997) 60-68
27. Diaz A., Pazos A., Flórez J., Ayesta F.J., Santana V., and Hurlé M.A. Regulation of μ-opioid receptors, G-protein-coupled receptor kinases and β-arrestin 2 in the rat brain after chronic opioid receptor antagonism. Neuroscience 112 (2002) 345-353
28. D'Sa C., and Duman R.S. Antidepressants and neuroplasticity. Bipolar Disord. 4 (2002) 183-194
29. 1A-autoreceptors regulating monoamine synthesis in the rat brain in vivo. Naunyn-Schmiedeberg's Arch. Pharmacol. 360 (1999) 135-143
30. Fan L.W., Tien L.-T., Tanaka S., Ma T., Chudapongse N., Sinchaisuk S., Rockhold R.W., and Ho I.K. Changes in the brain κ-opioid receptor levels of rats in withdrawal from physical dependence upon butorphanol. Neuroscience 121 (2003) 1063-1074
31. Ferrer-Alcón M., La Harpe R., and García-Sevilla J.A. Decreased immunodensities of μ-opioid receptors, receptor kinases GRK 2/6 and β-arrestin-2 in post-mortem brains of opiate addicts. Mol. Brain Res. 121 (2004) 114-122
32. Frigo G.M., Lecchini S., Marcoli M., Tonini M., D'Angelo L., and Crema A. Changes in sensitivity to the inhibitory effects of adrenergic agonists on intestinal motor activity after chronic sympathetic denervation. Naunyn Schmiedeberg's Arch. Pharmacol. 325 (1984) 145-152
33. Furness J.B., and Costa M. Sympathetic influences on gastrointestinal function in the enteric nervous system (1987), Churchill Livingstone, New York, NY 207-238
34. 2-adrenoceptor-mediated inhibition of platelet adenylate cyclase and induction of aggregation in major depression. Effect of long-term cyclic antidepressant drug treatment. Arch. Gen. Psychiatry 47 (1990) 125-132
35. i2 subunit and down-regulation by antidepressant drug treatment. Biol. Psychiatry 42 (1997) 704-712
36. 2A-adrenoceptors, Gi coupling proteins and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J. Neurochem. 72 (1999) 282-291
37. Giaroni C., De Ponti F., Cosentino M., Lecchini S., and Frigo G.M. Plasticity in the enteric nervous system. Gastroenterology 117 (1999) 1438-1458
38. Giaroni C., Somaini L., Marino F., Cosentino M., Senaldi A., De Ponti F., Lecchini S., and Frigo G.M. Modulation of enteric cholinergic neurons by hetero- and autoreceptors: cooperation among inhibitory inputs. Life Sci. 65 (1999) 813-821
39. Giaroni C., Zanetti E., Vanti A., Canciani L., Lecchini S., and Frigo G.M. Sympathetic denervation-induced changes in G protein expression in enteric neurons of the guinea pig colon. Life Sci. 71 (2002) 1961-1973
40. Heal D.J., Prow M.R., and Buckett W.R. Determination of the role of noradrenergic and 5-hydroxytryptaminergic neurons in postsynaptic alpha 2-adrenoceptor desensitization by desipramine and ECS. Br. J. Pharmacol. 103 (1991) 1865-1870
41. 2-adrenoceptors in antidepressant action: recent findings from microdialysis studies. Prog. Neuropsychopharmacol. Biol. Psychiatry 28 (2004) 819-827
42. Jewell-Motz E.A., and Liggett S.B. G protein-coupled receptor kinase specificity for phosphorylation and desensitisation of α2-adrenergic receptor subtypes. J. Biol. Chem. 271 (1996) 18082-18087
43. 2A-adrenergic receptors. Mol. Pharmacol. 64 (2003) 1317-1324
44. 2 adrenergic receptor agonists. Pain 87 (2000) 181-191
45. Kurjak M., Allescher H.D., Schusdziarra V., and Classen M. Release of bombesin-like immunoreactivity from synaptosomal membranes isolated from the rat ileum. Eur. J. Pharmacol. 257 (1994) 169-179
46. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
47. Lakhlani P.P., Lovinger D.M., and Limbird L.E. Genetic evidence for involvement of multiple effector systems in alpha 2A-adrenergic receptor inhibition of stimulus-secretion coupling. Mol. Pharmacol. 50 (1996) 96-103
48. Landabaso M.A., Iraurgi I., Jiménez-Lerma J.M., Sanz J., Fernádez de Corres B., Araluce K., Calle R., and Gutiérrez-Fraile M. A randomized trial of adding fluoxetine to a naltrexone treatment programme for heroin addicts. Addiction 93 (1998) 739-744
49. Langer S.Z. 25 years since the discovery of presynaptic receptors: present knowledge and future perspectives. Trends Pharmacol. Sci. 18 (1997) 95-99
50. Lefkowitz R.J. G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desentization. J. Biol. Chem. 273 (1998) 18677-18680
51. Lesch K.P., and Manji H.K. Signal-transducing G proteins and antidepressant drugs: evidence for modulation of α subunit gene expression in rat brain. Biol. Psychiatry 32 (1992) 549-579
52. (o) proteins and in neuroendocrine responses to a 5-HT1A agonist. J. Pharmacol. Exp. Ther. 279 (1996) 1035-1042
53. 2-adrenoceptor, opioid κ-receptor and adenosine A1-receptor interactions on noradrenaline release in rabbit brain cortex. Naunyn Schmiedeberg's Arch. Pharmacol. 338 (1988) 53-61
54. Magalas Z., De Vry J., and Tzschentke T.M. The serotonin/noradrenaline reuptake inhibitor venlafaxine attenuates acquisition, but not maintenance, of intravenous self-administration of heroin in rats. Eur. J. Pharmacol. 528 (2005) 103-109
55. 2-adrenoceptor agonists after chronic sympathetic denervation. Naunyn Schmiedeberg's Arch. Pharmacol. 329 (1985) 271-277
56. Marino F., Marcoli M., De Ponti F., Cosentino M., Lecchini S., and Frigo G.M. Effect of desipramine-induced blockade of neuronal uptake mechanisms on adrenoceptor-mediated responses in the guinea-pig colon. Naunyn Schmiedeberg's Arch. Pharmacol. 350 (1994) 499-506
57. Miller R.J. Presynaptic receptors. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 201-207
58. Miralles A., Asensio V.J., and García-Sevilla J.A. Acute treatment with the cyclic antidepressant desipramine, but not fluoxetine, increases membrane-associated G protein-coupled receptor kinases 2/3 in rat brain. Neuropharmacology 43 (2002) 1249-1257
59. Newmann M.E., and Lerer B. Post-receptor-mediated increases in adenylate cyclase activity after chronic antidepressant treatment: relationship to receptor desensitization. Eur. J. Pharmacol. 162 (1989) 345-352
60. Ozaita A., Escribá P.V., Ventayol P., Murga C., Mayor F., and García-Sevilla J.A. Regulation of G protein-coupled receptor kinase 2 in brains of opiate-treated rats and human opiate addicts. J. Neurochem. 70 (1998) 1249-1257
61. Pitcher J.A., Freedman N.J., and Lefkowitz R.J. G protein-coupled receptor kinases. Ann. Rev. Biochem. 67 (1998) 653-692
62. 2-adrenoceptors permits the operation of otherwise silent opioid κ-receptors at the sympathetic axons of rabbit jejunal arteries. Naunyn Schmiedeberg's Arch. Pharmacol. 334 (1986) 48-55
63. 2-adrenoceptors regulating monoamine synthesis in the brain of morphine-dependent rats. Naunyn Schmiedeberg's Arch. Pharmacol. 365 (2002) 210-219
64. 2A-adrenoceptor-deficient mice. Br. J. Pharmacol. 135 (2002) 697-704
65. 2-adrenoceptors attenuates the inhibitory effect of μ-opioid receptor agonists on noradrenaline release from brain slices. Naunyn Schmiedeberg's Arch. Pharmacol. 333 (1986) 377-380
66. Schulz R., Wehmeyer A., and Schulz K. Visualizing preference of G protein-coupled receptor kinase 3 for the process of κ-opioid receptor sequestration. Mol. Pharmacol. 61 (2002) 1444-1452
67. Shahbazian A., Heinemann A., Schmidhammer H., Beubler E., Holzer-Petsche U., and Holzer P. Involvement of mu- and kappa-, but not delta-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine. Br. J. Pharmacol. 135 (2002) 741-750
68. 2-adrenoceptors in rat brain are decreased after long-term tricyclic antidepressant drug treatment. Brain Res. 210 (1981) 413-418
69. Starke K., Göthert M., and Kilbinger H. Modulation of neurotransmitter release by presynaptic autoreceptors. Physiol. Rev. 69 (1989) 864-989
70. Sternini C., Patierno S., Selmer I.S., and Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol. Motil. 16 S2 (2004) 3-16
71. Sugrue M.F. Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. Pharmacol. Ther. 21 (1983) 1-33
72. Taylor D.A., Leedham J.A., Doak N., and Fleming W.W. Morphine tolerance and nonspecific subsensitivity of the longitudinal muscle myenteric plexus preparation of the guinea pig to inhibitory agonists. Naunyn Schmiedeberg's Arch. Pharmacol. 338 (1988) 553-559
73. Tso P.H., and Wong Y.H. Molecular basis of opioid dependence: role of signal regulation by G-proteins. Clin. Exp. Pharmacol. Physiol. 30 (2003) 307-316
74. Vilpoux C., Carpentier C., Leroux-Nicollet I., Naudon L., and Costentin J. Differential effects of chronic antidepressant treatments on μ- and δ-opioid receptors in rat brain. Eur. J. Pharmacol. 443 (2002) 85-93
75. Williams J.T., Christie M.J., and Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol. Rev. 81 (2001) 299-343